RECCE PHARMACEUTICALS LTD — Capital/Financing Update 2020

Sep 29, 2020

==> picture [416 x 93] intentionally omitted <==

ASX Announcement

Issue of Placement Shares

Sydney Australia, 30 September 2020: Recce Pharmaceuticals Ltd ( ASX: RCE ), the Company developing New Classes of Synthetic Anti-infectives, is pleased to advise that further to the announcement on 23 September 2020 regarding the completion of the $27.95m Capital Raising (Placement), the Placement shares have been allocated to investors who participated in the Placement today. Recce would like to extend a warm welcome to new and existing shareholders who participated in the Placement.

In addition to the Placement shares, the Company today has also allocated the unlisted options to Shaw & Partners Limited, as announced on 23 Setpember 2020.

The final allocation of shares completed today was the issue of ordinary share to Dr Graham Melrose following conversion of his Class D Performance Shares, announced to the market on 17 August 2020.

Following this announcement, the Company will release the Appendix 2A’s and 3G to detail the above issue of securities.

This announcement has been approved for release by Recce Pharmaceuticals CEO.

==> picture [595 x 57] intentionally omitted <==

About Recce Pharmaceuticals Ltd

Recce Pharmaceuticals Ltd (ASX: RCE) is pioneering the development and commercialisation of New Classes of Synthetic Anti-Infectives designed to address the urgent global health problems of antibiotic resistant superbugs and emerging viral pathogens.

Recce’s anti-infective pipeline is unique and comprised of broad-spectrum synthetic polymer antibiotics RECCE[®] 327 and RECCE[®] 435, and RECCE[®] 529 for viral infections with unique mechanisms of action against hyper-mutation on bacteria and viruses, respectively.

Patented lead candidate RECCE[®] 327 has been developed for the treatment of blood infections and sepsis derived from E. coli and S. aureus bacteria – including their superbug forms. Recce’s new antibiotic compound, RECCE[®] 435, has been formulated for oral use.

The FDA has awarded RECCE[®] 327 Qualified Infectious Disease Product designation under the Generating Antibiotic Initiatives Now (GAIN) Act – labelling it for Fast Track Designation, plus 10 years of market exclusivity post approval.

Recce wholly owns its automated manufacturing, ready to support first-in-human clinical trials. Recce’s anti-infective pipeline seeks to exploit the unique capabilities of RECCE[®] technologies targeting synergistic, unmet medical needs.

==> picture [581 x 93] intentionally omitted <==